A Randomised Trial of High Dose Therapy in Localised Cancer of the Prostate Using Conformal Radiotherapy Techniques
- Compare local tumor control in patients with stage II or III prostate cancer treated
with neoadjuvant androgen deprivation therapy with standard vs high-dose conformal
- Compare the incidence of biochemical failure (prostate-specific antigen (PSA) greater
than 2 ng/mL at 6 or more months after initiation of radiotherapy and PSA rising from
nadir level by at least 50%), development of metastases, and survival in patients
treated with these regimens.
- Compare the acute and late radiation-induced side effects of these regimens in this
- Compare aspects of quality of life, health economics, models of normal tissue, and
tumor control in patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
prostate-specific antigen, T stage, and Gleason score. Patients are randomized to one of two
All patients receive neoadjuvant androgen deprivation with luteinizing hormone-releasing
hormone agonists every 4 weeks beginning 3-6 months before initiation of radiotherapy and
continuing until completion of radiotherapy.
- Arm I: Patients undergo standard conformal radiotherapy for 6.5 weeks.
- Arm II: Patients undergo high-dose conformal radiotherapy for 7.5 weeks. Quality of
life is assessed at baseline, every 6 months for 2 years, and then annually thereafter.
Patients are followed every 6 months for 2 years and then annually thereafter.
PROJECTED ACCRUAL: A total of 800 patients will be accrued for this study.
Allocation: Randomized, Primary Purpose: Treatment
David P. Dearnaley, MD, FRCP, FRCR
Royal Marsden NHS Foundation Trust
United States: Federal Government